Windtree Sells Heart Drug Portfolio, Keeps Stake in Future Success

Windtree Therapeutics, Inc. has finalized an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC, a private investment group. This transaction allows Windtree to exit the costly and risky phase of development while maintaining a long-term economic interest tied to the future success of the assets.

Under the terms of the agreement, Seismic will take over Windtree’s cardiovascular portfolio and is responsible for its ongoing development. Windtree will retain a **20 percent** share of any future milestone payments, royalties, or other economic returns generated by the assets, including net revenues if the drugs are approved for market use. Additionally, the arrangement includes a contingent cash payment; should Seismic complete a financing round that raises at least **$10,000,000** for development, Windtree would receive **$700,000** from that funding.

Jed Latkin, Chief Executive Officer of Windtree, emphasized that this deal allows the company to step back from the financial burden of further development while still preserving significant potential upside. He stated, “The structure provides non-dilutive potential value through future proceeds and alleviates Windtree’s obligation to fund ongoing work on these assets.”

The drugs in question specifically target acute heart failure, a serious condition responsible for millions of hospitalizations annually. According to Windtree’s estimates, there were around **2.1 million** hospitalizations in the United States and **2.7 million** in the European Union in **2022**. The company has indicated that the global market for effective treatments for acute heart failure could be worth billions, highlighting both the size of the patient population and the current lack of innovative therapies.

Strategic Shift for Windtree

For Windtree, this agreement represents a significant strategic pivot toward monetizing its past research while improving its financial position. The decision to sell the cardiovascular assets reflects the company’s commitment to focusing on its core competencies without the encumbrance of ongoing development costs.

On the other hand, Seismic Pharmaceutical Holdings gains a valuable platform to advance crucial cardiovascular candidates in a field characterized by high unmet medical needs. Should these programs succeed, Windtree stands to benefit significantly from its retained economic interests.

This transaction not only strengthens Windtree’s balance sheet but also positions both companies to capitalize on the substantial market opportunity presented by acute heart failure treatments. As the healthcare landscape continues to evolve, partnerships like this one underscore the importance of strategic collaborations in addressing pressing medical challenges.